YY201
/ Yuyao Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 26, 2024
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
(clinicaltrials.gov)
- P1 | N=96 | Recruiting | Sponsor: Shanghai Yuyao Biotech Co., Ltd.
Metastases • New P1 trial • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1